Wittenberg Investment Management Inc. maintained its stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,026 shares of the company’s stock at the close of the second quarter. Wittenberg Investment Management Inc.’s holdings in Zoetis were worth $314,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Guardian Life Insurance Co. of America increased its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after acquiring an additional 13 shares during the period. Sii Investments Inc. WI increased its stake in shares of Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares during the period. Argent Trust Co increased its stake in shares of Zoetis by 0.8% in the first quarter. Argent Trust Co now owns 4,132 shares of the company’s stock worth $221,000 after acquiring an additional 32 shares during the period. Ironwood Investment Management LLC increased its stake in shares of Zoetis by 0.7% in the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares during the period. Finally, Benjamin F. Edwards & Company Inc. increased its stake in shares of Zoetis by 1.3% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares during the period. Institutional investors and hedge funds own 93.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Wittenberg Investment Management Inc. Maintains Stake in Zoetis Inc. (ZTS)” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/15/wittenberg-investment-management-inc-maintains-stake-in-zoetis-inc-zts.html.

Shares of Zoetis Inc. (NYSE:ZTS) traded up 0.37% during mid-day trading on Friday, reaching $65.49. 995,040 shares of the company were exchanged. The stock has a market capitalization of $32.03 billion, a P/E ratio of 37.02 and a beta of 1.02. The stock has a 50 day moving average price of $62.20 and a 200-day moving average price of $59.31. Zoetis Inc. has a 12 month low of $46.86 and a 12 month high of $65.83.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 EPS. Analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current year.

A number of analysts have recently weighed in on the stock. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. BMO Capital Markets lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and increased their price objective for the stock from $64.00 to $65.00 in a research note on Tuesday, June 13th. They noted that the move was a valuation call. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, August 14th. CL King assumed coverage on shares of Zoetis in a research note on Friday, May 26th. They issued a “buy” rating and a $71.00 price objective on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $65.44.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.